Aug 28, 2026 06:40PM
Aug 28, 2026 06:40PM
Aug 5, 2026 06:10PM
Aug 5, 2026 06:10PM
Jul 30, 2026 02:37AM
Jun 15, 2026 12:00PM
Jun 9, 2026 04:30PM FDA accepts Takeda's application for pediatric ENTYVIO treatment
Jun 9, 2026 04:30PM
May 13, 2026 05:46AM
May 13, 2026 02:38AM
Mar 2, 2026 06:01AM
Mar 2, 2026 02:00AM
Feb 10, 2026 04:50AM
Feb 10, 2026 03:15AM U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
Jan 14, 2026 09:00AM
Jan 5, 2026 07:03AM
Jan 5, 2026 07:00AM
Dec 8, 2025 02:54AM
Dec 6, 2025 09:30AM
Nov 21, 2025 11:54AM
Nov 7, 2025 11:01AM Takeda reports sustained kidney function benefits 18 months after treatment
Nov 7, 2025 11:00AM
Oct 27, 2025 08:35AM
Oct 21, 2025 08:25PM
Oct 21, 2025 08:25PM
Oct 21, 2025 08:25PM
Oct 21, 2025 08:25PM
Sep 8, 2025 03:00AM TAKEDA presents positive oveporexton phase 3 results for narcolepsy type 1
Sep 8, 2025 03:00AM
Sep 5, 2025 08:45PM
Sep 5, 2025 08:45PM
Jul 30, 2025 02:41AM
Jul 21, 2025 08:01AM
Jul 21, 2025 08:00AM
Jul 14, 2025 05:55AM Takeda reports positive phase 3 results for narcolepsy type 1 drug
Jul 14, 2025 03:00AM
Jun 30, 2025 08:00AM
Jun 3, 2025 10:13AM
Jun 3, 2025 10:12AM
Jun 1, 2025 08:00AM
May 21, 2025 09:32AM
May 14, 2025 05:10PM Takeda (TAK) announces publication of data from Phase 2b trial of Tak-861
May 14, 2025 05:03PM
May 5, 2025 08:00AM
Mar 3, 2025 06:46AM
Mar 3, 2025 06:45AM
Dec 3, 2024 07:00AM
Nov 7, 2024 07:00AM
Sep 24, 2024 03:00AM Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
Sep 19, 2024 08:00AM

330,234 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All